{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-214504","form_type":"8-K","ticker":"VCNX","cik":"0001205922","company_name":"VACCINEX, INC.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.153192+00:00","generated_at":"2026-06-24T02:37:03.142335+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vaccinex announces publication of Phase 2 SIGNAL HD study in Nature Medicine showing pepinemab slows cognitive decline","bullets":["Phase 2 SIGNAL HD study results published in Nature Medicine (Aug 8, 2022) and Journal of Neuroinflammation.","Pepinemab significantly improved cognition in early manifest HD patients (HD-CAB Index p=0.007).","Pepinemab reduced caudate atrophy (p=0.017) and brain metabolic decline in FDG-PET.","Treatment was well-tolerated with 5% treatment-emergent adverse events vs 9% placebo.","Phase 1b/2a study of pepinemab in Alzheimer's disease initiated (NCT04381468)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-214504","json":"https://secwatch.observer/filing/0001193125-22-214504.json","markdown":"https://secwatch.observer/filing/0001193125-22-214504.md","text":"https://secwatch.observer/filing/0001193125-22-214504.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1205922/000119312522214504/0001193125-22-214504-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1205922/000119312522214504/d320536d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:37:03.142335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}